8-K: HeartSciences Inc. Formalizes $15 Million Unit Offering and Series D Preferred Stock Designation

HeartSciences Inc. has formalized its $15 million unit offering, including Series D Preferred Stock and warrants, and designated the Series D Preferred Stock, as part of its capital raising efforts.

Summary

• HeartSciences Inc. (the "Company") filed an Offering Statement on Form 1-A on February 12, 2025, which was qualified by the SEC on March 10, 2025.
• The offering is for up to 4,285,714 units at an offering price of $3.50 per unit, aiming for a maximum offering amount of $15,000,000.
• Each unit consists of one share of the Company's Series D Preferred Stock and one warrant to purchase one share of common stock at an exercise price of $5.00 per share.
• Effective March 10, 2025, the Company entered into a Selling Agency Agreement with Digital Offering, LLC to act as the sole placement agent on a best efforts basis for the Offering.
• The placement agent will receive a cash fee of 7% of the gross proceeds and warrants (Agent Unit Warrants) to purchase 3% of the total units sold, with an exercise price of $4.375 per Agent Unit Warrant.
• On May 28, 2025, the Company was notified that its Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Stock was filed with the Texas Secretary of State, effective May 21, 2025, designating 4,285,714 shares of Series D Preferred Stock.

Sentiment

Score: 6

Explanation: The filing details the formalization of a capital raise, which is generally positive for a company seeking funding to advance its operations. However, the 'best efforts' nature of the offering and the significant agent fees introduce some uncertainty regarding the total funds raised and potential future dilution, preventing a higher score.

Positives

• Formalization of a capital raising mechanism, potentially providing up to $15,000,000 in funding for the Company's operations and strategic initiatives.
• Engagement of Digital Offering, LLC as a sole placement agent to facilitate the offering, leveraging external expertise for capital generation.
• SEC qualification of the Offering Statement on Form 1-A on March 10, 2025, indicating regulatory approval for the offering structure and allowing it to proceed.

Negatives

• The offering is on a "best efforts basis," meaning there is no guarantee that the full $15,000,000 maximum offering amount will be raised, introducing uncertainty regarding funding.
• Significant fees and warrants (7% cash fee and 3% Agent Unit Warrants) payable to the placement agent will reduce the net proceeds received by the Company and could lead to future equity dilution.

Risks

• The "best efforts" nature of the offering means the Company may not raise the maximum target amount of $15,000,000, which could impact its financial liquidity and operational plans.
• Potential dilution risk for existing common stockholders due to the issuance of new Series D Preferred Stock, warrants, and additional Agent Unit Warrants to the placement agent.
• Future exercise of warrants by unit holders and the placement agent could lead to an increase in the number of outstanding common shares, potentially exerting downward pressure on the common stock price.

Future Outlook

The document details the structure and formalization of an ongoing capital raise through a unit offering. It does not provide specific forward-looking financial guidance, operational forecasts, or future performance expectations beyond the mechanics of the offering itself.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEARTSCIENCES INC. Date: June 3, 2025 By: /s/ Andrew Simpson Name: Andrew Simpson Title: President, Chief Executive Officer and Chairman of the Board of Directors"

Industry Context

This filing is specific to HeartSciences Inc.'s capital raising activities. It reflects a common strategy for smaller public companies, particularly those in the medical device or health technology sector (implied by 'HeartSciences'), to raise capital through unit offerings that combine preferred stock and warrants. This method, often utilizing placement agents on a best-efforts basis, allows companies to secure funding for operations, research and development, or market expansion, which is a typical need for growth-oriented firms in specialized industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing common stockholders face potential dilution from the issuance of new Series D Preferred Stock and warrants, as well as the Agent Unit Warrants issued to the placement agent.
• Investors in the Offering: Will acquire Series D Preferred Stock and warrants, providing them with specific rights and potential upside if the common stock price increases above the warrant exercise price.
• Company: Gains access to potential capital (up to $15,000,000) to fund operations, research, and development, but incurs costs through placement agent fees and potential future dilution from warrant exercises.
• Placement Agent (Digital Offering, LLC): Benefits from cash fees and warrants for facilitating the capital raise.

Next Steps

• Completion of the unit offering through subsequent closings, as the offering is ongoing.
• Potential exercise of warrants by unit holders and the placement agent, which would lead to the issuance of additional common stock.

Key Dates

Keywords

HeartSciences, HSCS, SEC filing, 8-K, capital raise, unit offering, Series D Preferred Stock, warrants, Digital Offering LLC, placement agent, equity financing, corporate governance, stock designation